Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly subcutaneous navepegritide (ACP-015) for 52 weeks in children with achondroplasia
jRCT2061250056Active, not recruiting
- Sponsor
- Teijin Pharma
- Start
- Nov 2025
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of navepegritide in achondroplasia (ACH), sponsored by Teijin Pharma. Primary endpoint: Change in ACH-specific height Z-score from baseline to Week 52. Started Nov 2025; status: active, not recruiting.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on jRCT2061250056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250056.